Interclean Shanghai

NASA Awards Grants for Technologies That Could Transform Space Exploration

NASA has selected eight university-led proposals to study innovative, early stage technologies that will address high-priority needs of America's space program.
NASA Logo.

The selected proposals for unique, disruptive or transformational space technologies will investigate challenges in the areas of solar cell operations at high temperatures, atmospheric entry model development, synthetic biology applications for space exploration and dynamic tensegrity-based space structures. Tensegrity is a property of structures that employs continuous tension and discontinuous compression to produce exceptionally strong structures for their mass.

"These early career researchers will provide fuel for NASA's innovation engine," said Steve Jurczyk, associate administrator for NASA's Space Technology Mission Directorate at the agency's Headquarters in Washington. "Technology drives exploration, and investments in these technologies and technologists is essential to ensure NASA and the nation have the capabilities necessary to meet the challenges we will face as we journey to Mars. The faculty selected and their colleagues help assure a robust university research community dedicated to advanced space technology development."

The awards are approximately $200,000 per year, up to a possible three years of research, for outstanding early-career faculty who research space technologies that are high priorities for NASA missions.

The selected NASA Early Career Faculty proposals are:

    Robust Planning for Dynamic Tensegrity Structures — Kostas Bekris of Rutgers

University in New Brunswick, New Jersey
    Synthetic Biology for Recycling Human Waste into Food, Nutraceuticals, and Materials: Closing the Loop for Long-Term Space Travel — Mark Blenner of Clemson

University in Clemson, South Carolina
    Lightweight and Flexible Metal Halide Perovskite Thin Films for High Temperature

Solar Cells — Joshua Choi of the University of Virginia in Charlottesville Dynamics and Control of Tensegrity Space Manipulators — James Forbes of the

University of Michigan, Ann Arbor
    Advanced Physical Models and Numerical Algorithms to Enable High-Fidelity Aerothermodynamic Simulations of Planetary Entry Vehicles on Emerging Distributed Heterogeneous Computing Architectures — Matthias Ihme of Stanford University in Stanford, California

    Reduced Order Modeling for Non-equilibrium Radiation Hydrodynamics of Base Flow and Wakes: Enabling Manned Missions to Mars — Marco Panesi of the University of illinois, Urbana-Champaign Engineering Cyanobacteria for the Production of Lightweight Materials — Fuzhong

Zhang of Washington University in St. Louis
    High Temperature InGaN-based Solar Cells — Yuji Zhao, Arizona State University, Tempe.

These proposals have the potential to yield significant rewards for space exploration by:   allowing solar cells to function at reasonable levels of efficiency in high-temperature Environments;   improving the process of identifying the most effective thermal protection systems for entering various atmospheres;  providing the means to produce food, medical supplies and building materials on site at distant destinations using synthetic, biology-based approaches; and   enabling more capable and affordable space missions through the development of tensegrity technologies that permit large, reconfigurable structures such as antennas, solar arrays and observatories, as well as lightweight landers.

NASA's Early Career Faculty efforts are an element of the agency's Space Technology Research Grants Program. This program is designed to accelerate the development of technologies originating from academia that support the future science and exploration needs of NASA, other government agencies and the commercial space sector.

FDA warns makers of superbug-prone devices over testing violations

Manufacturers of medical devices linked to recent superbug outbreaks at U.S. hospitals skirted a host of testing, manufacturing and reporting requirements, the U.S. Food and Drug Administration said in warning letters to the companies released on Monday.

The letters, sent on Aug. 12, cite Olympus Corp Pentax Medical and Fujifilm Holdings Corp with multiple violations found during inspections of their U.S. and foreign facilities.

Violations range from not properly evaluating cleaning, sterilization and testing procedures to failure to report infections and other problems. Fujifilm and Pentax were also cited for violations in their marketing applications for the devices, known as duodenoscopes.

"The FDA takes these violations very seriously and will continue to monitor these firms to ensure they take appropriate corrective action," the agency said in a statement. "However, currently available information indicates that the benefits of these devices continue to outweigh the risks in appropriately selected patients."
The reusable devices are flexible instruments snaked down a patient's throat to diagnose or treat disorders of the gastrointestinal tract. About 500,000 of the procedures take place every year in the United States.

The FDA first warned of their potential to transmit antibiotic-resistant germs in 2009. Since then duodenoscopes have been implicated in superbug outbreaks at multiple U.S. hospitals, including one last year that may have exposed 179 patients at UCLA's Ronald Reagan Medical Center.

The FDA conducted inspections at all three companies' facilities earlier this year. In addition to testing and reporting violations the agency found that Pentax and Fujifilm had failed to apply for proper approval of one or more devices.

Fujifilm claimed that its ED-530XT device was very similar to the ED-450XT5, which had been cleared by the FDA. Device makers are not required to file for separate clearance of a device if changes made are minor. But they must explain, in a document kept on file should the FDA ever want to see it, why they did not file for clearance.

In the case of Fujifilm's device, the FDA determined that there were significant differences between the ED-450XT5 and the ED-530XT and that a new 510(k) application was needed to demonstrate that the device was safe and effective and that it was substantially equivalent to a legally marketed device.

The FDA is also examining Pentax's justifications for not filing for 510(k) clearance of its ED-3670TK scope and changes made to its ED-3490TK device.

Vibra Healthcare acquires Two Inpatient Rehabilitation Hospitals

Vibra Healthcare announced that a Vibra affiliate recently acquired two acute medical rehabilitation hospitals from Elmcroft Senior Living of Louisville, KY. The hospitals are Gateway Rehabilitation Hospital at Florence, a 40-bed, 62,550 square foot facility located in Florence, KY; and Highlands Regional Rehabilitation Hospital, a 41-bed, 50,839 square foot facility located in El Paso, TX.

The hospitals collectively employ 370 medical professionals and staff and provide specialized inpatient and outpatient medical rehabilitative care for patients recovering from stroke, spinal cord injuries, brain injuries and neurological illnesses.

"We are pleased to add these two outstanding acute medical rehabilitation hospitals to the Vibra family of specialty acute care hospitals. This acquisition further strengthens our strategic objectives of increasing our acute rehabilitation market footprint and providing exceptional patient care," stated Brad Hollinger, chairman and chief executive officer of Vibra Healthcare. "As the nation's population continues to live longer with more active lifestyles, now, more than ever, acute medical rehabilitation hospitals are an essential part of patients' paths to full recovery."

GE Healthcare First to Receive FDA Clearance for Low Dose CT Lung Cancer Screening

GE Healthcare is proud to be the first company with a low dose computed tomography (CT) lung cancer screening option

[i] that is cleared by the U.S. FDA for lung cancer screening.
[ii] Both the U.S. Preventative Services Task Force (USPSTF) and the Centers for Medicare and Medicaid Services (CMS) recommend the use of low dose CT lung cancer screening for high-risk individuals.
[iii], [iv] Additionally, Medicare has approved insurance reimbursement for its beneficiaries who are eligible for the use of low dose CT lung cancer screening in high-risk patients.
[v] Early detection from an annual lung cancer screening with low dose CT in high-risk persons can prevent a substantial number of lung cancer–related deaths.
[iv]Bringing low dose CT screening to patients at a high risk for lung cancer will reduce death from the most deadly cancer worldwide,” said Dr. Ella Kazerooni, chair of committee on lung cancer screening, American College of Radiology. “Performing low dose CT with attention to high image quality at the lowest radiation exposure to detect early cancer is at the core of a successful screening program, and requires collaboration with imaging partners to bring technology to bear for this purpose. The FDA’s clearance of these CT scanners for this purpose illustrates that commitment.”

Physicians using low dose CT for lung cancer screening will now have access to the benefits from a screening indication, including GE Healthcare’s new low-dose screening reference protocols. These new protocols are tailored to the CT system, patient size, and the most current recommendations from a wide range of professional medical and governmental organizations. Now, qualified GE Healthcare CT scanners can be confidently used by physicians within their FDA cleared indications for use, delivering low dose, short scan times, and clear and sharp images for the detection of small lung nodules. These nodules are critical in identifying lung cancer at its earliest stages when it is the most treatable and curable.[vi]

The landmark National Lung Screening Trial (NLST) was conducted at 33 medical institutions with over 53,000 older, otherwise healthy patients at high-risk due to smoking history. Half of the participants were screened using low dose CT, the other half were screened using chest X-ray. The trial demonstrated that the use of low dose CT screening decisively reduced the mortality rate from lung cancer by 20 percent compared to use of chest X-ray. The NLST also revealed a significant 6.7 percent reduction in the rate of death from any cause using low dose CT screening.[vii]

All new 64-slice and greater CT scanners, and virtually all of the 16-slice CT scanners that GE Healthcare sells are qualified systems and will include the screening option. The solution that GE Healthcare developed is also available to thousands of qualified GE scanners currently in use, increasing access to the quality scanners that satisfy both patient and physician needs. The new protocols are able to utilize GE Healthcare’s industry-leading technologies such as ASiRTM, ASiR-VTM and VeoTM that are designed to reduce image noise, which is undesirable for physicians looking for small nodules.

In the United States, lung cancer is the third most common cancer and the leading cause of cancer deaths; it kills almost twice as many women as breast cancer and three times as many men as prostate cancer. Survival rates from lung cancer are highly correlated to its initial stage at the time of first diagnosis. The overall five year survival rate for lung cancer is among the lowest (17 percent) of all types of cancer but is significantly higher when the cancer is diagnosed at an early stage (54 percent). However, currently only 15 percent of lung cancer cases are diagnosed at such an early stage.[viii],

[ix] The use of low dose CT lung cancer screening increases this percentage of early stage detection, providing patients a much better prognosis.

“This is the first time in history that any CT device has received FDA clearance for any screening indication,” said Henry Hummel, president and CEO of Molecular Imaging and CT at GE Healthcare. “GE Healthcare is thrilled to be the first CT vendor who can help clinicians establish low dose CT lung screening programs in order to continue improving the health of their patients. Healthcare providers are looking for solutions beyond just imaging equipment; we look forward to helping them establish low dose CT lung cancer screening programs that will inevitably save lives through earlier diagnosis and treatment for patients.”

National Hemophilia Foundation’s 67th Annual Meeting:Astronaut Dr. Mae Jemison & Bayer Bring Science

Bayer HealthCare will host an event for members of the bleeding disorders community, patients and their families during the National Hemophilia Foundation's (NHF) Annual Meeting taking place August 13-15 in Dallas, Texas.  The dinner event will feature a keynote address from Dr. Mae Jemison, the first African-American woman astronaut, who will share her love of exploration, meeting challenges and growing up.

Also a physician, engineer and accomplished children's author, Dr. Jemison is Bayer's long-time ambassador and advocate for its award-winning "Making Science Make Sense" initiative, which advances science literacy across the United States through hands-on learning, public education, and employee volunteerism. Dr. Jemison's talk will highlight the importance of STEM (science, technology, engineering and math) education, not just for students pursuing STEM careers but for all of us in our everyday lives.

"I believe that all children are innately interested in science," said Dr. Jemison.  "Frequently young people with chronic illnesses are even more likely to be engaged in and knowledgeable about science, as they gain an early command of concepts about their body and the environment in order to understand their disease and manage their health."  

"Bayer has a long, proud history of working with the bleeding disorders community, and our STEM education initiatives have often aligned closely with issues that are important to patients and their families," said Dario Mirski, MD, Vice President U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals. "We must invest in our young people so they can be prepared for success as potential future innovators."

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Medical Care, and Pharmaceuticals divisions. As a specialty pharmaceutical company, Bayer HealthCare provides products for General Medicine, Hematology, Neurology, Oncology and Women's Healthcare. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

Red Cross Helping People on Saipan As Two New Tropical Systems Target the U.S. Island

The American Red Cross continues to provide emergency relief on Saipan even as residents prepare for two new tropical storms threatening this remote U.S. territory.American Red Cross.

Typhoon Soudelor blasted Saipan, part of the U.S. Commonwealth of the Northern mariana Islands, last week, leaving most of the island without power, water and sewer facilities. The new tropical systems are likely to bring new flooding and further damage the battered island.

"For an island devastated by a massive typhoon and left with no electricity or water, these people are incredibly good natured and generous," said Julie Bradley, a Red Cross volunteer from Arizona deployed to Saipan. "There is a real fear here in Saipan that although they are part of the American territories in the Pacific, they will be overlooked by the traditional generosity of Americans towards one another."

Typhoon Soudelor damaged more than 1,100 homes, including nearly 600 that were destroyed or suffered major damage. With a local office on Saipan and a group of dedicated volunteers, the Red Cross helped people prepare as Typhoon Soudelor moved in and was on site immediately to support sheltering, feeding and damage assessment efforts.

Thousands of people – more than 4,600 – have already called seeking help. More than 200 people spent Thursday night in government-operated shelters and that number is likely to increase over the weekend as the new tropical systems bring heavy rain and high winds to the island. The Red Cross has already provided more than 14,000 meals and handed out more than 26,000 emergency relief items.

"Right now the people of Saipan depend on the Red Cross for the supplies of daily living; everything from food to cooking and cleaning items," continued Bradley. "Recovery will be long and expensive, and I hope that although Saipan is far from the mainland, generous donors keep them in mind."

Because of the extensive damage, the Red Cross has created a robust relief plan to get immediate help to people who need it. The program combines financial assistance with critical supplies to help people begin to recover. Relief supplies include items such as rice, canned foods, hygiene products and cleaning supplies for thousands of people in the hardest hit areas.

CONNECTING WITH FAMILY It's important that those affected by these tropical storms stay in contact with loved ones and the Red Cross Safe and Well website can help people do that. Safe and Well is a secure, easy-to-use online tool to help families connect in an emergency. People can register by visiting redcross.org or calling 1-800-RED CROSS (1-800-733-2767).         

HOW TO HELP People can help by donating to Red Cross Disaster Relief by visiting redcross.org, calling 1-800-RED CROSS or texting the word REDCROSS to 90999 to make a $10 donation. Donations to Disaster Relief will be used to prepare for, respond to and help people recover from disasters big and small. We respond to nearly 70,000 other disasters every year, from home fires to hurricanes, typhoons and more. Learn more about how Disaster Relief donations have helped people affected by previous disasters including home fires.

About the American Red Cross:

The American Red Cross shelters, feeds and provides emotional support to victims of disasters; supplies about 40 percent of the nation's blood; teaches skills that save lives; provides international humanitarian aid; and supports military members and their families. The Red Cross is a not-for-profit organization that depends on volunteers and the generosity of the American public to perform its mission. For more information,

please visit redcross.org or visit us on Twitter at @RedCross.

Johnson Health Tech Agrees to Pay $3 Million Civil Penalty for Failure to Report Defective Fitness

The U.S. Consumer Product Safety Commission (CPSC) announced today that Johnson Health Tech Co. Ltd, of Taiwan, and Johnson Health Tech North America Inc., of Cottage Grove, Wis., have agreed to pay a $3 million civil penalty. The civil penalty agreement settles CPSC staff's charges that Johnson Health Tech knowingly failed to report to CPSC immediately, as required by federal law, regarding a defect and an unreasonable risk of serious injury with Matrix Fitness Ascent Trainers and Elliptical Trainers.

The U.S. Consumer Product Safety Commission is an independent federal agency created by Congress in 1973 and charged with protecting the American public from unreasonable risks of serious injury or death from more than 15,000 types of consumer products under the agency's jurisdiction. To report a dangerous product or a product-related injury, call the CPSC hotline at 1-800-638-2772, or visit http//:www.cpsc.gov/talk.html. Further recall information is available at
http://www.cpsc.gov.

The fitness trainers' defect involved a build-up of moisture in the power sockets of the units from perspiration or cleaning liquids, which caused the machines to short circuit. Between March 2012 and October 2013, Johnson Health Tech received multiple reports of smoking, sparking or melted power components and reports of fires involving the trainers. Despite these reports and two design changes to fix the problem, Johnson Health Tech failed to report the defect, the consumer incidents or the design changes to CPSC immediately (within 24 hours). There were no injuries or property damage reported.

The Matrix Fitness Ascent Trainers and Elliptical Trainers were recalled in January 2014, after Johnson Health Tech had manufactured, imported and sold more than 3,000 units nationwide. The firm sold the trainers from September 2011 through December 2012 for between $6,000 and $11,000 each.

In addition to paying the $3 million civil penalty, Johnson Health Tech North America has agreed that the company has, and will maintain, a compliance program to ensure compliance with the Consumer Product Safety Act (CPSA) and a related system of internal controls and procedures.

The compliance program requires written standards, policies, and written procedures to ensure that all information regarding the firm's compliance with the CPSA, including reports and complaints, is conveyed to the firm's responsible employees, whether an injury is referenced or not. The compliance program also must address:

  •     confidential employee reporting of compliance concerns to a senior manager;
  •     effective communication of compliance policies and procedures, including training;
  •     senior management responsibility for, and board oversight of compliance; and
  •     requirements for record retention.

Johnson Health Tech does not admit to CPSC staff's charges.

The penalty agreement has been accepted provisionally by the Commission by a 3 to 2 vote.

http://www.cpsc.gov/en/Newsroom/News-Releases/2015/Johnson-Health-Tech-Agrees-to-Pay-3-Million-Civil-Penalty-for-Failure-to-Report-Defective-Fitness-Equipment/

CPSC Consumer Information Hotline

Contact us at this toll-free number if you have questions about a recall:800-638-2772 (TTY 301-595-7054)
Times: 8 a.m. – 5:30 p.m. ET; Messages can be left anytime
Call to get product safety and other agency information and to report unsafe products.

Media Contact

Please use the phone numbers below for all media requests.
Phone: 301-504-7908
Spanish: 301-504-7800

1-800 Contacts Holds Ribbon Cutting Ceremony for New Corporate Headquarters.

1-800 Contacts, Inc. celebrated its new corporate headquarters today with a ribbon cutting ceremony. The company moved to a new state-of-the art facility in the Draper Pointe development at 261 W. Data Drive, just west of I-15 and north of Bangerter Highway. 1-800 Contacts associates were joined by Draper City dignitaries as well as their construction partners Gardner Company, The Boyer Company and L&T Construction for the event.

"We're thrilled with our new headquarters facility which houses all of our corporate departments in one building," said Brian Bethers, CEO of 1-800 Contacts. "We've created a work environment that inspires collaboration and better enables us to grow our business."

1-800 Contacts occupies 100,000 square feet of the LEED certified building and features floor-to-ceiling windows that maximize natural lighting and an improved on-site restaurant and wellness center.

1-800 Contacts is the largest retailer of contact lenses in the United States and has had its headquarters located in Draper, Utah since 1997.

Pennsylvania DHS Secretary,Representatives & Commissioner to visit health association

PA Department of Human Services (DHS) Secretary Ted Dallas, Representatives Madeleine Dean and  Mary Jo Daley, and Montgomery County Commissioner Josh Shapiro will be joined by Pottstown-area human services providers at the Mental Health Association of Southeastern Pennsylvania to request the General Assembly to provide adequate funding for human service programs in the 2015-16 budget.

WHAT: DHS Secretary Ted Dallas visits Mental Health Association of Southeastern Pennsylvania to advocate for adequate human services funding.
WHEN: Monday, August 17, 2015, 11 a.m.
WHERE: Mental Health Association of Southeastern Pennsylvania, 249 E. High Street, Pottstown, PA 19464

MEDIA CONTACT: Kait Gillis, 717-425-7606

Endo Announces U.S. District Court Ruling Upholding OPANA® ER Intellectual Property

 Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that the U.S. District Court for the Southern District of New York has issued a ruling upholding two Endo patents covering OPANA® ER, the Company's opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The ruling also determined that Endo's patents had been infringed by all of the defendants. As a result, it is expected that the generic version of non-crush-resistant OPANA® ER currently sold by Actavis, the U.S. generics business of Allergan, Inc., will be removed from the market and additional approved but not yet marketed generic versions of the product developed by other generic companies will not be launched in the near term.

"Endo has long been dedicated to vigorously asserting and defending our patents for OPANA® ER," said Rajiv De Silva, President and CEO of Endo. "We are very happy with today's outcome and are reviewing the ruling in greater detail to determine its long-term impact. We remain committed to advancing OPANA® ER and to making it available to patients for responsible and appropriate use."

In December 2012, Endo filed a patent infringement complaint against Actavis in U.S. District Court for the Southern District of New York for patent infringement based on Actavis' sale of a non-crush-resistant generic version of OPANA® ER. In 2013, Endo filed similar suits in the U.S. District Court for the Southern District of New York against the following additional applicants for non-crush-resistant OPANA® ER: Par Pharmaceutical, Teva Pharmaceuticals, Mallinckrodt LLC, Sandoz, Roxane and Ranbaxy. The suits against par Pharmaceutical and Mallinckrodt LLC have been dismissed pursuant to settlements and the suits against Teva Pharmaceuticals and Sandoz have been dismissed based on those companies' demonstration to Endo that they do not intend to pursue an ANDA for non-crush-resistant OPANA® ER.

About OPANA® ER

OPANA® ER is a strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough to require daily, around-the-clock, long-term treatment with an opioid, when other pain treatments such as, non-opioid pain medicines or immediate-release opioid medicines do not treat your pain well enough or you cannot tolerate them. OPANA® ER is a long-acting (extended-release) opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed, you are at risk for opioid addiction, abuse, and misuse that can lead to death. OPANA® ER is not for use to treat pain that is not around-the-clock. It is not known if OPANA® ER is safe and effective in children under 18 years of age. The full prescribing information and Medication Guide for OPANA® ER is available at www.opana.com . Also, read the boxed warning and additional safety information below.

Important Safety Information for OPANA® ER

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and INTERACTION WITH ALCOHOL

Addiction, Abuse, and Misuse OPANA® ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing OPANA® ER, and monitor all patients regularly for the development of these behaviors or conditions.

Life-threatening Respiratory Depression serious, life-threatening, or fatal respiratory depression may occur with use of OPANA®

ER. Monitor for respiratory depression, especially during initiation of OPANA® ER or following a dose increase. Instruct patients to swallow OPANA® ER tablets whole; crushing, chewing, or dissolving OPANA® ER tablets can cause rapid release and absorption of a potentially fatal dose of oxymorphone.

Accidental Ingestion

Accidental ingestion of even one dose of OPANA® ER, especially by children, can result in a fatal overdose of oxymorphone.

Neonatal Opioid Withdrawal Syndrome prolonged use of OPANA® ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Interaction with Alcohol

Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products that contain alcohol while taking OPANA® ER. The co-ingestion of alcohol with OPANA® ER may result in increased plasma levels and a potentially fatal overdose of oxymorphone.

Contraindications

OPANA® ER is contraindicated in patients with:

  •     Significant respiratory depression
  •     Acute or severe bronchial asthma or hypercarbia
  •     Known or suspected paralytic ileus and gastrointestinal obstruction
  •     Moderate and severe hepatic impairment
  •     Hypersensitivity (e.g. anaphylaxis) to oxymorphone, any other ingredients in OPANA® ER, or to morphine analogs such as codeine


About Endo International plc

Endo International plc is a global specialty pharmaceutical company focused on improving patients' lives while creating shareholder value. Endo develops, manufactures, markets and distributes quality branded pharmaceutical and generic pharmaceutical products as well as over-the-counter medications though its operating companies. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan,"

"will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Although Endo believes that these forward-looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward-looking statements or information in this news release. Investors should note that many factors, as more fully described in the documents filed by Endo with securities regulators in the united States and Canada including under the caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and with securities regulators in Canada on System for Electronic Document Analysis and

Retrieval ("SEDAR") and as otherwise enumerated herein or therein, could affect Endo's future financial results and could cause Endo's actual results to differ materially from those expressed in forward-looking statements contained in Endo's Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause Endo's actual results to differ materially from expected and historical results. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws.

1...849850851...1,090Page 850 of 1,090

About us

Hospital & healthcare Management is a leading B2B arena designed for the healthcare sector, it allow members to reach both ends of the healthcare facility procurement chain.

Subscribe us

System

Resources

Archive Links

Subscribe

Copyright © 2005 - 2019 Global Hospital & Healthcare Management. Designed by Leo Marcom Pvt.Ltd.

Translate »